P. Bacher

发表

Effects of Calcium Channel Blockers on Proteinuria in Patients With Diabetic Nephropathy

R. Toto, A. Champion, Min Tian, 2008, Journal of clinical hypertension.

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation

U. Tunn, P. Bacher, D. Gruca, 2013, Clinical interventions in aging.

Erratum: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome (Diabetes Care (2006) 29 (2592-2597))

G. Bakris, J. Sowers, M. Molitch, 2007 .

A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model.

J. Fareed, O. Iqbal, J. Walenga, 1993, Thrombosis research.

Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs.

D. Hoppensteadt, J. Fareed, R. Pifarré, 1992, Progress in cardiovascular diseases.

Evaluation of Hemostatic and Fibrinolytic Alterations Associated with Daily Administration of Low-Molecular-Weight Heparin for a 12-Week Period

D. Hoppensteadt, J. Fareed, D. Hoppensteadt, 1995, Seminars in thrombosis and hemostasis.

Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.

G. Bakris, A. Champion, Qian Zhou, 2008, Journal of the cardiometabolic syndrome.

Safety and tolerability of intermittent androgen deprivation therapy: A literature review

U. Tunn, P. Bacher, D. Gruca, 2012, International journal of urology : official journal of the Japanese Urological Association.

Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.

D. Hoppensteadt, J. Fareed, Sarfraz Ahmad, 2002, Thrombosis research.

Blood Coagulation and Anticoagulant Drugs

J. Fareed, W. Jeske, J. Walenga, 2003 .

Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.

W. Jeske, J. Walenga, M. Bakhos, 2004, Seminars in thrombosis and hemostasis.

Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma

D. Hoppensteadt, J. Fareed, W. Jeske, 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Drug-induced alterations of hemostasis and fibrinolysis.

J. Fareed, P. Bacher, R. Bick, 1992, Hematology/oncology clinics of North America.

The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model.

D. Hoppensteadt, J. Fareed, O. Iqbal, 1992, Thrombosis research.

Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide.

D. Hoppensteadt, J. Fareed, O. Iqbal, 1993, Seminars in thrombosis and hemostasis.

Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients.

M. Gent, V. Marzinotto, P. Massicotte, 2003, Thrombosis research.

The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.

K. Breddin, J. Fareed, O. Iqbal, 1993, Thrombosis research.

Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.

D. Hoppensteadt, J. Fareed, O. Iqbal, 1994, Thrombosis research.

Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate

A. Soliman, K. Klein, P. Bacher, 2018, Journal of pediatric endocrinology & metabolism : JPEM.

Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation

Peter A. Lee, P. Bacher, M. Luce, 2016, Journal of pediatric endocrinology & metabolism : JPEM.

36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.

N. Mauras, K. Klein, Peter A. Lee, 2014, The Journal of clinical endocrinology and metabolism.

Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug "defibrotide". A dual mechanism in the control of vascular pathology.

J. Fareed, J. Walenga, P. Bacher, 1993, Thrombosis research.

Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model.

J. Fareed, R. Pifarré, J. Walenga, 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Risk factor assessment for new onset diabetes: literature review

G. Bakris, Qian Zhou, J. Sowers, 2009, Diabetes, obesity & metabolism.

Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials

K. Unnebrink, M. Sánchez Luna, P. Bacher, 2020, Journal of Perinatology.

Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

Arya M. Sharma, C. Torp‐Pedersen, A. Maggioni, 2008, Journal of cardiovascular pharmacology.

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.

P. Kowey, G. Mancia, S. Bangalore, 2008, American heart journal.

Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test

D. Hoppensteadt, J. Fareed, O. Iqbal, 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Advances in Heparins and Related Research. An Epilogue

J. Fareed, W. Jeske, P. Bacher, 2018, Molecules.

Some Objective Considerations for the Use of Heparins and Recombinant Hirudin in Percutaneous Transluminal Coronary Angioplasty

D. Hoppensteadt, J. Fareed, R. Pifarré, 1991, Seminars in thrombosis and hemostasis.

P. Kowey, G. Mancia, S. Bangalore, 2008, American heart journal.

Antihypertensive properties of a high‐dose combination of trandolapril and verapamil‐SR

F. Messerli, C. Pepine, W. Frishman, 2007, Blood pressure. Supplement.